We found that both the tumor specific TCF-1+ and TCF-1- TIM-3+ populations substantially increased in tumor 1 and tumor 2 after combination therapy compared to either monotherapy alone with no significant changes in their relative frequencies (Fig. 1e–g, Supplementary Fig. 1f, g). The gene discussed is HAVCR2; the disease is neoplasm.